A phase 1, single-centre, randomised, double-blind, placebo-controlled, single ascending dose study to investigate the safety, tolerability and pharmacokinetics of intravenous and subcutaneous CSL312 in healthy subjects.
Latest Information Update: 21 Apr 2021
At a glance
- Drugs Garadacimab (Primary) ; Garadacimab (Primary)
- Indications Hereditary angioedema
- Focus Adverse reactions
- Sponsors CSL
- 01 Mar 2021 Results presented at the 2021 Annual Meeting of the American Academy of Allergy, Asthma and Immunology
- 18 Dec 2017 Status changed from active, no longer recruiting to completed.
- 12 Jul 2017 Status changed from not yet recruiting to active, no longer recruiting.